Article
Depressive symptoms and Vitamin D in patients with early arthritis
Search Medline for
Authors
-
Desiree Freier
- Charité - Universitätsmedizin Berlin, Medizinische Klinik mit Schwerpunkt Rheumatologie und klinische Immunologie, Berlin
-
Maria Biersack
- Charité - Universitätsmedizin Berlin, Medizinische Klinik mit Schwerpunkt Rheumatologie und klinische Immunologie, Berlin
-
Vera Höhne-Zimmer
- Charité - Universitätsmedizin Berlin, Medizinische Klinik mit Schwerpunkt Rheumatologie und klinische Immunologie, Berlin
-
Vivien Köhler
- Charité - Universitätsmedizin Berlin, Medizinische Klinik mit Schwerpunkt Rheumatologie und klinische Immunologie, Berlin
-
Gerd-Rüdiger Burmester
- Charité - Universitätsmedizin Berlin, Medizinische Klinik mit Schwerpunkt Rheumatologie und klinische Immunologie, Berlin
-
Tanja Braun
- Charité - Universitätsmedizin Berlin, Medizinische Klinik mit Schwerpunkt Rheumatologie und klinische Immunologie, Berlin
-
Ralf Uebelhack
- Charité - Universitätsmedizin Berlin, Klinik für Psychiatrie und Psychotherapie, Berlin
-
Jacqueline Detert
- Charité - Universitätsmedizin Berlin, Medizinische Klinik mit Schwerpunkt Rheumatologie und klinische Immunologie, Berlin
| Published: | September 4, 2017 |
|---|
Outline
Text
Background: There is a high prevalence of depression in patients with rheumatic disorders. Especially, in rheumatoid arthritis, it is one of the most prevalent co-morbidities with 16% to 38%. Vitamin D (VD) deficiency is one of the known risk factors for depressive disorders. On the other hand, a VD deficiency has often been detected in rheumatic diseases. A possible correlation between these two co-morbidities has not been investigated so far in patients with early arthritis (EA).
Objectives: The aim of this study was to examine the association between VD deficiency and depression and/or anxiety disorders in patients who have presented themselves for the first time in the EA clinic
Methods: Patients with a suspected EA (at least one swollen joint without previous trauma or joint infection with a symptom duration of 6 weeks to 12 months) received a screening date within five work days. The VD status (25-hydroxy-VD3) was obtained during the first EA clinic consultation. In addition, each patient completed questionnaires on the disease history, as well as evaluated self-assessment questionnaires including the health assessment questionnaire (HAQ) and the Hospital Anxiety and Depression Scale (HADS). The hereby-obtained results of disease activity, VD-status and HADS-scores were investigated. In the observation period from June 2012 to March 2015, 75 patients fulfilled the inclusion criteria of completed results and questionnaires as well as a disease duration of less than 12 months.
Results: The mean age of this EA cohort was 51.7±16.9 years (♀ 65.3%, mean disease duration: 4.0±3.0 months). The prevalence of VD deficiency (<75 nmol/l) was 73.3%. 48.0% of EA patients showed a positive global distress score (≥ 13). The mean HADS global distress score in VD sufficient patients was 10.2±8.6 vs 13.3±6.9 in deficient patients. The observed difference was not statistically significant. There was neither an association between gender, age and VD status nor was there any difference in the laboratory parameters (e.g. C-reactive protein, rheumatic factor, anti citrullinated peptide, hemoglobine) or assessment of functional status (e.g. HAQ, disease activity score by 28 joints).
Conclusion: The prevalence of VD deficiency is higher in EA patients with 73% than in the general German population (vs. 60%). The prevalence of positive distress with 50% is also higher. Interestingly, no association of deficient VD levels and positive distress in the HADS was detected in our examined EA cohort. This might be explained by the early stage of disease, but further studies are necessary to evaluate this new insight.
